Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncolog

Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor program Building on recent announcements, this collaboration with Accent

Related Keywords

Saclay , France General , France , Qi Wang , Hubei , China , Shanghai , United States , Wei Wang , Gansu , Paris , Yin Dong , Guangdong , Cambridge , Cambridgeshire , United Kingdom , Yong Li , Guizhou , American , Jennifer Gordon , Benjamind Wheeler , Ipsen Euronext , Christelle Huguet , Zacharya Gurard Levin , Oumin Shi , Michaeld Scholle , Shakti Narayan , Jess Smith , Quanxiang Zeng , Roberta Copeland , P Ann Boriack Sjodin , Xiaoquin Lu , Scott Ribich , Jeffreyl Hirsch , Shanem Buker , Head Of Global Communications , Head Of Research , Early Development , Spectrum Science Communications , Business Development , American Cancer Society , Accent Therapeutics , Senior Vice President , External Innovation , Chief Executive Officer , Rare Disease , Consumer Healthcare , Total Sales , Sponsored Leveli American Depositary Receipt , French Autorit , Des March , Acute Myeloid , Hematology Oncology , Aprilw Case , Mass Spectrometric Assay , Investor Relations , Relations Manager , Science Communications , Lipsen , Odds , Another , Program , Into , Linical , Ncology , Pipeline , Through , Exclusive , Orldwide , Collaboration , Ith , Accent , Herapeutics , Targeting , Modifying , Protein , Ettl3 ,